{"product_id":"cocp-vrio-analysis","title":"Cocrystal Pharma, Inc. (COCP): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Cocrystal Pharma, Inc. (COCP) truly built to last? This VRIO analysis cuts straight to the core, dissecting its resources and capabilities through the rigorous lens of Value, Rarity, Inimitability, and Organization to reveal its true competitive standing. Discover immediately whether Cocrystal Pharma, Inc. (COCP) possesses the sustainable advantage that separates market leaders from the rest - the full, distilled breakdown awaits below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 1. Structure-Based Drug Discovery Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Cocrystal Pharma, the structure-based drug discovery platform. This isn't just some abstract R\u0026amp;D concept; it’s the technology that’s actively generating their pipeline, which is currently focused on influenza, norovirus, and coronaviruses. The immediate takeaway is that this platform is currently providing a \u003cstrong\u003etemporary\u003c\/strong\u003e competitive advantage, heavily reliant on converting its scientific promise into approved drugs.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s value proposition is clear: it allows them to engineer next-generation, broad-spectrum antivirals by precisely targeting conserved viral regions. Think about norovirus - there is currently no FDA-approved treatment or prevention for it. Cocrystal’s lead candidate, CDI-988, which targets this platform, is positioned as a potential first-in-class treatment for this highly contagious illness. Furthermore, their influenza candidate, CC-42344, showed a favorable safety profile in its recently completed Phase 2a study as of November 2025. This ability to target multiple high-need areas is where the value truly sits.\u003c\/p\u003e\n\n\u003cp\u003eHonestly, the platform’s rarity is high because while structure-based design is a known field, Cocrystal’s specific application and demonstrated success rate in generating these novel compounds seem unique to them right now. This is underscored by the fact that the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded them an approximately \u003cstrong\u003e$500,000\u003c\/strong\u003e Small Business Innovation Research (SBIR) Phase I grant in October 2025 specifically to advance their influenza program using this technology. That’s non-dilutive capital validating the science.\u003c\/p\u003e\n\n\u003cp\u003eTo be fair, imitability is only medium-to-high. The underlying structural biology science isn't secret, but replicating the specific, proprietary compound library and the deep institutional know-how - the subtle art of translating a structure into a viable drug candidate - takes significant time and investment. It’s not a simple copy-paste job.\u003c\/p\u003e\n\n\u003cp\u003eOrganizationally, they are definitely using it well. They are actively advancing multiple programs, and the NIH funding is a clear sign of external validation. As of September 30, 2025, they had \u003cstrong\u003e$7.7 million\u003c\/strong\u003e in unrestricted cash, bolstered by recent financings totaling \u003cstrong\u003e$4.7 million\u003c\/strong\u003e gross proceeds in September 2025 and another \u003cstrong\u003e$1.03 million\u003c\/strong\u003e in October 2025. This cash position supports the continued development, like the expected Q1 2026 start for the norovirus challenge study for CDI-988. They are organized to push these assets forward.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this platform:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eSupporting Data\/Implication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue (V)\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eEnables first-in-class potential for unmet needs like Norovirus (CDI-988).\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity (R)\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eValidated by recent \u003cstrong\u003e$500,000\u003c\/strong\u003e NIH\/NIAID SBIR Phase I award in October 2025.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability (I)\u003c\/td\u003e\n    \u003ctd\u003eNo (Costly\/Time-consuming)\u003c\/td\u003e\n    \u003ctd\u003eRequires significant time and know-how to replicate the specific compound library.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization (O)\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eActively advancing Influenza (CC-42344) and Norovirus (CDI-988) programs.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eAdvantage persists only until a successful drug is approved or a competitor replicates the know-how.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is that the net loss for the first nine months of 2025 was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e, meaning this platform needs to deliver clinical success to justify the burn rate. The temporary advantage hinges entirely on the next set of clinical readouts.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s success is tied to specific pipeline milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvance CDI-988 into Q1 2026 norovirus challenge study.\u003c\/li\u003e\n\u003cli\u003eTranslate CC-42344 Phase 2a safety data into a path for future influenza trials.\u003c\/li\u003e\n\u003cli\u003eSecure a larger Phase II NIH award based on Phase I success.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: review the Q4 2025 cash runway projection based on the \u003cstrong\u003e$7.7 million\u003c\/strong\u003e cash balance as of September 30, 2025, by Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 2. Proprietary Intellectual Property (Lead Candidates)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides market exclusivity and a barrier to entry for competitors targeting the same viral replication mechanisms with CDI-988 and CC-42344.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; most biotechs have IP, but the breadth covering multiple high-value viruses is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patents are legally protected, making direct imitation impossible until expiration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Medium; IP management seems standard, but the value is tied directly to the clinical success of the protected compounds.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (while patents are in force); this is the legal foundation of their potential future revenue stream.\u003c\/p\u003e\n\u003cp\u003eThe proprietary intellectual property is anchored by the structure-based drug discovery platform technology, which has yielded lead candidates targeting viral replication enzymes and proteases. The intangible asset related to acquired IPR\u0026amp;D, stemming from the November 2014 acquisition of RFS Pharma, was recorded at an estimated fair value of $184,966,000 as of the acquisition date.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCandidate\u003c\/td\u003e\n\u003ctd\u003eTarget Indication(s)\u003c\/td\u003e\n\u003ctd\u003eLatest Clinical Status Detail\u003c\/td\u003e\n\u003ctd\u003eAssociated Market Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDI-988\u003c\/td\u003e\n\u003ctd\u003eNorovirus\/Coronavirus (including SARS-CoV-2)\u003c\/td\u003e\n\u003ctd\u003ePhase 1b trial for Norovirus prevention\/treatment planned for Q1 2026 enrollment. Favorable safety\/tolerability from SAD cohorts reported July 2024.\u003c\/td\u003e\n\u003ctd\u003eGlobal COVID-19 therapeutics market estimated to exceed $16 billion annually by the end of 2031.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCC-42344\u003c\/td\u003e\n\u003ctd\u003eInfluenza A (including pandemic\/seasonal\/H5N1)\u003c\/td\u003e\n\u003ctd\u003ePhase 2a human challenge study completed November 2025; showed favorable safety profile with no SAEs. Active against the 2024 Texas H5N1 avian influenza strain.\u003c\/td\u003e\n\u003ctd\u003eDevelopment continues for pandemic and seasonal Influenza A treatment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company reported unrestricted cash of $7.7 million and working capital of $7.3 million as of September 30, 2025, with 13.0 million common shares outstanding.\u003c\/p\u003e\n\u003cp\u003eKey milestones and attributes related to the IP-protected compounds include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCC-42344 exhibited activity against the highly pathogenic 2024 Texas H5N1 avian influenza strain.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCC-42344 Phase 2a study in the UK reported favorable safety and tolerability with no serious adverse events (SAEs) and no drug-related discontinuations.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCDI-988 exhibited superior \u003cem\u003ein vitro\u003c\/em\u003e potency against SARS-CoV-2.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe Phase 1 study for CC-42344 reported favorable safety and tolerability results in December 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 3. Lead Candidate CDI-988 (Norovirus\/Coronavirus)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Addresses a massive, unmet medical need (no FDA-approved norovirus treatment) with demonstrated broad-spectrum activity against prevalent 2024-2025 strains like GII.17. The Norovirus Infection Treatment Market was valued at \u003cstrong\u003eUSD 93.94 million\u003c\/strong\u003e in the year \u003cstrong\u003e2024\u003c\/strong\u003e, projected to reach \u003cstrong\u003eUSD 152.24 million\u003c\/strong\u003e by \u003cstrong\u003e2031\u003c\/strong\u003e at a CAGR of \u003cstrong\u003e7.1%\u003c\/strong\u003e, or alternatively estimated at \u003cstrong\u003e1.398 USD Billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e, projected to reach \u003cstrong\u003e3.483 USD Billion\u003c\/strong\u003e by \u003cstrong\u003e2035\u003c\/strong\u003e with a CAGR of \u003cstrong\u003e8.65%\u003c\/strong\u003e. Norovirus accounts for nearly \u003cstrong\u003e20%\u003c\/strong\u003e of all acute gastroenteritis cases worldwide.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; it is positioned as a potential first-in-class oral treatment\/prophylaxis for norovirus. CDI-988 has shown in vitro pan-viral activity against multiple norovirus strains, including GII.4 and GII.17.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; competitors could develop other protease inhibitors, but CDI-988 has a significant head start in clinical readiness. The development is supported by Cocrystal's proprietary structure-based drug discovery platform technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is clearly prioritizing this, having completed Phase 1 and secured FDA clearance for a Q1 2026 challenge study. The company reported unrestricted cash of \u003cstrong\u003e$7.7 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, and working capital of \u003cstrong\u003e$7.3 million\u003c\/strong\u003e as of the same date. The company strengthened its balance sheet through financings, including a registered direct offering in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e raising gross proceeds of \u003cstrong\u003e$4.7 million\u003c\/strong\u003e and a private placement in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e raising gross proceeds of \u003cstrong\u003e$1.03 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the first-mover advantage is strong, but only until a competitor’s drug is approved or if Phase 1b results are poor. The platform's validation is further supported by an NIH SBIR Phase I award of approximately \u003cstrong\u003e$500,000\u003c\/strong\u003e for its influenza program.\u003c\/p\u003e\n\u003cp\u003eMarket Data Context for CDI-988:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (2024\/2025)\u003c\/td\u003e\n\u003ctd\u003eProjected Value\/CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorovirus Market Size (Estimate 1)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 93.94 Million\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 152.24 Million\u003c\/strong\u003e by 2031 (CAGR \u003cstrong\u003e7.1%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorovirus Market Size (Estimate 2)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.398 USD Billion\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3.483 USD Billion\u003c\/strong\u003e by 2035 (CAGR \u003cstrong\u003e8.65%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorovirus Share of Acute Gastroenteritis\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e20%\u003c\/strong\u003e Worldwide\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDI-988 Clinical Milestone\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Completed\u003c\/td\u003e\n\u003ctd\u003ePhase 1b Challenge Study Start: \u003cstrong\u003eQ1 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Unrestricted Cash\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.7 Million\u003c\/strong\u003e (as of \u003cstrong\u003eSep 30, 2025\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eClinical Development Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReceived FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment.\u003c\/li\u003e\n\u003cli\u003ePhase 1 study reported favorable safety and tolerability results from single-ascending dose cohorts (\u003cstrong\u003eJuly 2024\u003c\/strong\u003e) and multiple-ascending dose cohorts (\u003cstrong\u003eDecember 2024\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eCDI-988 exhibits activity against key circulating strains, including GII.\u003cstrong\u003e17\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 4. Lead Candidate CC-42344 (Influenza)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a potential oral treatment for pandemic and seasonal Influenza A, a recurring global health threat.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInfluenza causes approximately \u003cstrong\u003e1 billion\u003c\/strong\u003e cases annually worldwide, resulting in \u003cstrong\u003e3-5 million\u003c\/strong\u003e cases of severe illness and up to \u003cstrong\u003e650,000\u003c\/strong\u003e deaths.\u003c\/li\u003e\n\u003cli\u003eOn average about \u003cstrong\u003e8%\u003c\/strong\u003e of the U.S. population contracts influenza each season.\u003c\/li\u003e\n\u003cli\u003eCC-42344, a novel oral PB2 inhibitor, has shown excellent \u003cem\u003ein vitro\u003c\/em\u003e activity against pandemic and seasonal Influenza A strains, including strains resistant to \u003cstrong\u003eTamiflu®\u003c\/strong\u003e and \u003cstrong\u003eXofluza®\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many flu antivirals exist, but a novel mechanism targeting the PB2 polymerase complex offers resistance advantages.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCC-42344 targets the PB2 polymerase complex, an essential function of the influenza polymerase complex.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; the specific molecule is protected, but the general target area is known in the field.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCC-42344 is a novel oral \u003cstrong\u003ePB2 inhibitor\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe compound was developed using Cocrystal's proprietary structure-based drug discovery platform technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Medium; despite the efficacy data challenge in the Phase 2a study, they continue development and secured \u003cstrong\u003e$500,000\u003c\/strong\u003e in \u003cstrong\u003eNIH\u003c\/strong\u003e funding to advance it.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 1 study for oral CC-42344 reported favorable safety and tolerability results in December 2022.\u003c\/li\u003e\n\u003cli\u003eThe randomized, double-blind, placebo-controlled Phase 2a human challenge study began in December 2023 in the United Kingdom, enrolling \u003cstrong\u003e78\u003c\/strong\u003e healthy subjects.\u003c\/li\u003e\n\u003cli\u003eEnrollment in the Phase 2a study was completed in May 2024.\u003c\/li\u003e\n\u003cli\u003eIn December 2024, a plan was announced to extend the Phase 2a study due to unexpectedly low influenza infection among participants.\u003c\/li\u003e\n\u003cli\u003eCocrystal received a Small Business Innovation Research (SBIR) Phase I award from the \u003cstrong\u003eNIH\/NIAID\u003c\/strong\u003e for approximately \u003cstrong\u003e$500,000\u003c\/strong\u003e in October 2025 to support development.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, the company had working capital of \u003cstrong\u003e$7.3 million\u003c\/strong\u003e and unrestricted cash of \u003cstrong\u003e$7.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company plans to release topline results from the Phase 2a study in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh Potential\u003c\/td\u003e\n\u003ctd\u003eAddresses a market with approximately \u003cstrong\u003e1 billion\u003c\/strong\u003e annual cases globally.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eNovel mechanism targeting PB2 polymerase complex offers resistance advantages over existing drugs like \u003cstrong\u003eTamiflu®\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eSpecific molecule protected, but general target area is known; relies on proprietary structure-based technology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eSecured \u003cstrong\u003e$500,000\u003c\/strong\u003e in non-dilutive \u003cstrong\u003eNIH\u003c\/strong\u003e funding in October 2025 to continue development despite Phase 2a extension.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eProgram is lagging lead candidate \u003cstrong\u003eCDI-988\u003c\/strong\u003e; success contingent on overcoming Phase 2a limitations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 5. Expertise in Antiviral Drug Development (Nobel Prize-winning)\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe presence of Nobel Prize-winning expertise lends significant credibility to the company's platform and drug candidates when engaging with investors, potential partners, and regulatory agencies such as the FDA. This expertise underpins the structure-based drug discovery technology platform.\u003c\/p\u003e\n\u003cp\u003eFinancial metrics reflecting ongoing commitment and potential value derived from this expertise include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment from Merck Deal (Influenza)\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Payments from Merck Deal\u003c\/td\u003e\n\u003ctd\u003eFuture\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$156 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH SBIR Award Received\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Global COVID-19 Therapeutics Market\u003c\/td\u003e\n\u003ctd\u003eBy End of 2031\u003c\/td\u003e\n\u003ctd\u003eExceed \u003cstrong\u003e$16 billion\u003c\/strong\u003e Annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eDirect association with Nobel Prize-winning expertise in the core science of antiviral drug discovery is exceptionally rare within the small-cap biotechnology sector.\u003c\/p\u003e\n\u003cp\u003eKey personnel associated with this rare expertise include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRoger Kornberg, Ph.D.: Chairman of the Board, Chief Scientist, and Chairman of the Scientific Advisory Board. Awarded the \u003cstrong\u003eNobel Prize in Chemistry in 2006\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMichael Levitt, Ph.D.: Member of the Scientific Advisory Board. A \u003cstrong\u003eNobel Laureate in Chemistry\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific scientific lineage and knowledge base derived from Nobel Prize-winning research, particularly in structural biology and molecular mechanisms of transcription, cannot be easily hired or replicated through standard recruitment.\u003c\/p\u003e\n\u003cp\u003eThe proprietary approach builds on a technique developed in Dr. Kornberg's lab, utilizing X-ray crystallography to assess compound binding at near-atomic resolution, which is difficult to replicate without the foundational knowledge.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTechnology provides a three-dimensional structure of inhibitor complexes at \u003cstrong\u003enear-atomic resolution\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses for the full year 2024 were \u003cstrong\u003e$12.5 million\u003c\/strong\u003e, compared with $15.2 million for 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis foundational expertise is deeply embedded within the company’s structure, driving its discovery process and pipeline advancement.\u003c\/p\u003e\n\u003cp\u003eOrganizational structure supporting this expertise includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eIndividual\u003c\/th\u003e\n\u003cth\u003eAssociation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChairman of the Board, Chief Scientist, Chairman of Scientific Advisory Board\u003c\/td\u003e\n\u003ctd\u003eRoger Kornberg, Ph.D.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2006 Nobel Laureate\u003c\/strong\u003e in Chemistry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMember, Scientific Advisory Board\u003c\/td\u003e\n\u003ctd\u003eMichael Levitt, Ph.D.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNobel Laureate\u003c\/strong\u003e in Chemistry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresident and co-CEO\u003c\/td\u003e\n\u003ctd\u003eSam Lee, Ph.D.\u003c\/td\u003e\n\u003ctd\u003eLeads pipeline advancement, including norovirus\/coronavirus candidate CDI-988\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial performance metrics demonstrating ongoing operations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for the first nine months of 2025 was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e, or $0.61 per share.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the full year 2024 was \u003cstrong\u003e$17.5 million\u003c\/strong\u003e, or $1.72 per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is considered \u003cstrong\u003eSustained\u003c\/strong\u003e due to the difficulty in replicating the foundational knowledge base that underpins all of Cocrystal's assets and its structure-based drug discovery platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 6. Non-Dilutive Funding Access (NIH SBIR Awards)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides crucial capital, like the recent \u003cstrong\u003e$500,000\u003c\/strong\u003e award in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e, to fund R\u0026amp;D without diluting existing shareholder equity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many small biotechs seek grants, but successfully securing competitive NIH funding validates the science externally. The award was a Phase I SBIR award from the National Institute of Allergy and Infectious Diseases (NIAID) under award number \u003cstrong\u003e75N93025C00038\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; it depends on the specific scientific merit of the proposal and the current NIH funding priorities. Successful completion of Phase I may qualify the company to apply for a larger Phase II award.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management actively pursues and secures this funding, showing capital efficiency focus. At the time of the award announcement, Cocrystal's market capitalization was \u003cstrong\u003e$15.4 million\u003c\/strong\u003e, and the company maintained a current ratio of \u003cstrong\u003e3.69\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it is project-specific and not a continuous, guaranteed resource.\u003c\/p\u003e\n\u003cp\u003eThe non-dilutive funding supports the development of a novel, oral, broad-spectrum antiviral candidate targeting influenza A and B infections.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH SBIR Award Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 2025, Phase I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAwarding Body\u003c\/td\u003e\n\u003ctd\u003eNIAID (NIH)\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAward Number\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75N93025C00038\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch Support Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Market Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare Price (at announcement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.18\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.69\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Financial Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company has prioritized the pursuit of government and military funding to advance its antiviral pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe funds will be used to characterize lead candidate molecules that inhibit the essential function of the influenza polymerase complex.\u003c\/li\u003e\n\u003cli\u003eSuccessful Phase I completion makes the company eligible to apply for a Phase II award, which provides additional substantial funding.\u003c\/li\u003e\n\u003cli\u003eThis non-dilutive capital contrasts with concurrent equity financing, such as the September 2025 registered direct offering that raised gross proceeds of \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 7. Cash Position and Recent Financing Strength (Late 2025)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAs of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, unrestricted cash totaled \u003cstrong\u003e$7.7 million\u003c\/strong\u003e. Working capital stood at \u003cstrong\u003e$7.3 million\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (as of 9\/30\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorking Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nFinancing activity demonstrates market access:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross proceeds of \u003cstrong\u003e$4.7 million\u003c\/strong\u003e from a registered direct offering and private placement in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds of \u003cstrong\u003e$1.03 million\u003c\/strong\u003e from a private placement with directors and management in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdditional non-dilutive NIH SBIR award of \u003cstrong\u003e$500,000\u003c\/strong\u003e in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe recent capital raises reflect current investor confidence in the near-term pipeline progression.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe enhanced cash position provides a runway to fund the planned initiation of the \u003cstrong\u003eCDI-988\u003c\/strong\u003e norovirus challenge study in \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e; the cash buffer must be managed against the operating burn rate, which was \u003cstrong\u003e$6.5 million\u003c\/strong\u003e over the \u003cstrong\u003enine months of 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 8. Targeting High-Value, Unmet Medical Needs\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focusing on diseases like norovirus and pandemic influenza offers the potential for blockbuster sales due to the lack of current effective options.\u003c\/p\u003e\n\u003cp\u003eNorovirus represents a pressing unmet need with an estimated worldwide societal cost of approximately \u003cstrong\u003e$60 billion\u003c\/strong\u003e annually, associated with \u003cstrong\u003e685 million\u003c\/strong\u003e global cases each year. There is currently no effective treatment or vaccine for norovirus. The global seasonal influenza market was valued at \u003cstrong\u003e$6.5 billion\u003c\/strong\u003e in 2021 and is projected to reach up to \u003cstrong\u003e$27.95 billion\u003c\/strong\u003e by 2029.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many companies target large markets, but few target the specific niche of an oral, broad-spectrum norovirus prophylactic\/treatment.\u003c\/p\u003e\n\u003cp\u003eCDI-988 is positioned as the \u003cstrong\u003efirst\u003c\/strong\u003e novel, oral drug candidate for the prevention and treatment of norovirus infection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can pivot to these markets, but Cocrystal has a head start with clinical data.\u003c\/p\u003e\n\u003cp\u003eCDI-988 has completed Phase 1 trials with favorable safety and tolerability results. The company received FDA clearance for a Phase 1b challenge trial of CDI-988, set to start in Q1 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire pipeline is strategically aligned to these high-impact, high-return areas.\u003c\/p\u003e\n\u003cp\u003ePipeline development is supported by recent financing activities and focused R\u0026amp;D spending:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss for the first nine months of 2025 was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the first nine months of 2025 was \u003cstrong\u003e$6.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUnrestricted cash as of September 30, 2025, was \u003cstrong\u003e$7.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds of \u003cstrong\u003e$4.7 million\u003c\/strong\u003e were raised from a registered direct offering in September 2025, with a potential additional \u003cstrong\u003e$8.3 million\u003c\/strong\u003e from warrant exercises.\u003c\/li\u003e\n\u003cli\u003eAn NIH SBIR award of \u003cstrong\u003e$500,000\u003c\/strong\u003e was granted in October 2025 to advance the influenza program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\/Target\u003c\/td\u003e\n\u003ctd\u003eCandidate\u003c\/td\u003e\n\u003ctd\u003eStatus\/Data Point\u003c\/td\u003e\n\u003ctd\u003eMarket\/Impact Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorovirus\u003c\/td\u003e\n\u003ctd\u003eCDI-988\u003c\/td\u003e\n\u003ctd\u003ePhase 1 safety\/tolerability complete; Phase 1b challenge study enrollment expected Q1 2026.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$60 billion\u003c\/strong\u003e societal cost; \u003cstrong\u003e685 million\u003c\/strong\u003e global cases annually.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfluenza A\/B\u003c\/td\u003e\n\u003ctd\u003eCC-42344\u003c\/td\u003e\n\u003ctd\u003ePhase 2a challenge study yielded no meaningful efficacy data due to low infection rates.\u003c\/td\u003e\n\u003ctd\u003eSeasonal market projected to reach \u003cstrong\u003e$27.95 billion\u003c\/strong\u003e by 2029.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; market opportunity is high, but the advantage is only held until a competitor launches a similar product.\u003c\/p\u003e\n\u003cp\u003eCDI-988 has demonstrated broad-spectrum antiviral activity against dominant norovirus strains GII.4 and GII.17.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCocrystal Pharma, Inc. (COCP) - VRIO Analysis: 9. Clinical Development Experience (Phase 1 Completion)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Successfully completing Phase 1 safety trials for CDI-988 (up to the \u003cstrong\u003e1200 mg cohort\u003c\/strong\u003e) de-risks the compound significantly for future partners or investors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many companies have Phase 1 data, but completing it across high doses for a novel target is a key milestone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; the experience gained running the trial is hard to copy, but the process itself is standard.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the team has demonstrated the ability to execute complex trials, even if the CC-42344 Phase 2a efficacy was inconclusive. The execution is reflected in financial performance metrics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended June 30, 2024\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.8 million\u003c\/strong\u003e (as of June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this milestone is passed, and the advantage shifts to the next stage: successful Phase 1b results.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCDI-988 Phase 1 data presented included all doses ranging from \u003cstrong\u003e100 mg to 1200 mg\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCC-42344 Phase 2a human challenge study enrolled \u003cstrong\u003e78 subjects\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe CC-42344 Phase 2a study was extended due to \u003cstrong\u003eunexpectedly low influenza infection\u003c\/strong\u003e among participants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Finalize the Q4 2025 cash burn projection by end of next week. The net cash used in operating activities for the first six months of 2025 was \u003cstrong\u003e$5.1 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516141199509,"sku":"cocp-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cocp-vrio-analysis.png?v=1740161325","url":"https:\/\/dcf-model.com\/es\/products\/cocp-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}